Publications by authors named "Gabrielle Betty Rocque"
Article Synopsis
- Patients with early-stage triple-negative breast cancer (TNBC) face a high risk of recurrence after treatment, even when receiving pembrolizumab alongside chemotherapy.
- Sacituzumab govitecan, which combines an antibody-drug conjugate with a topoisomerase I inhibitor, shows significant improvement in progression-free survival and overall survival for pre-treated metastatic TNBC compared to traditional chemotherapy.
- The international phase III AFT-65/ASCENT-05/OptimICE-RD trial aims to assess the effectiveness and safety of sacituzumab govitecan combined with pembrolizumab versus physician's choice treatment for early-stage TNBC patients who have residual disease post-neoadjuvant therapy, and is currently recruiting participants
Background: Breast cancer patients experienced heightened anxiety during the pandemic. Also, modifications to clinical trial activities allowing for virtual platforms, local assessments, and greater flexibility were introduced to facilitate participation. We sought to evaluate the association between pandemic-related anxiety and willingness to participate in trials and how pandemic-era modifications to trial activities affect the decision to participate.
View Article and Find Full Text PDFValue-based health systems encompass a range of care-delivery models from small independent practices to large integrated delivery systems and academic medical centers. In addition, public and private payers, federal and state agencies, professional societies, and not-for-profit organizations collect and analyze data for quality and value improvement in health care-delivery outcomes. In this article, we review the multidimensional aspects of data collection, aggregation, analysis, and use for and by value-based health systems.
View Article and Find Full Text PDF